PHOTOCURE ASA (PHO.OL) Stock Price, Forecast & Analysis
Europe - OSL:PHO - NO0010000045 - Common Stock
PHO.OL Key Statistics, Chart & Performance
The current stock price of PHO.OL is 58.7 NOK. In the past month the price increased by 8.1%. In the past year, price increased by 11.17%.
PHO.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 11.85 | 219.36B | ||
| SAN.PA | SANOFI | 11.86 | 219.51B | ||
| MRK.DE | MERCK KGAA | 13.6 | 50.30B | ||
| UCB.BR | UCB SA | 35.93 | 44.87B | ||
| BAYN.DE | BAYER AG-REG | 5.8 | 28.53B | ||
| 1BAYN.MI | BAYER AG-REG | 5.81 | 28.59B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 27.13 | 11.18B | ||
| IPN.PA | IPSEN | 12.59 | 10.84B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 97.36 | 9.01B | ||
| VIRP.PA | VIRBAC SA | 20.62 | 3.00B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 17.09 | 1.83B | ||
| MEDCL.PA | MEDINCELL SA | N/A | 1.02B |
Related stock screener links
About PHO.OL
Company Profile
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 101 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Company Info
PHOTOCURE ASA
Hoffsveien 4
Oslo OSLO NO
Employees: 100
Phone: 4722062210
PHOTOCURE ASA / PHO.OL FAQ
What does PHO do?
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 101 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Can you provide the latest stock price for PHOTOCURE ASA?
The current stock price of PHO.OL is 58.7 NOK. The price increased by 2.98% in the last trading session.
What is the dividend status of PHOTOCURE ASA?
PHO.OL does not pay a dividend.
What is the ChartMill rating of PHOTOCURE ASA stock?
PHO.OL has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for PHOTOCURE ASA?
The Revenue of PHOTOCURE ASA (PHO.OL) is expected to grow by 11.99% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for PHO stock?
PHOTOCURE ASA (PHO.OL) will report earnings on 2026-02-17, after the market close.
Who owns PHOTOCURE ASA?
You can find the ownership structure of PHOTOCURE ASA (PHO.OL) on the Ownership tab.
PHO.OL Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PHO.OL. When comparing the yearly performance of all stocks, PHO.OL is a bad performer in the overall market: 60.91% of all stocks are doing better.
PHO.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL. PHO.OL has a great financial health rating, but its profitability evaluates not so good.
PHO.OL Financial Highlights
Over the last trailing twelve months PHO.OL reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS decreased by -93.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| Debt/Equity | 0 |
PHO.OL Forecast & Estimates
8 analysts have analysed PHO.OL and the average price target is 81.09 NOK. This implies a price increase of 38.14% is expected in the next year compared to the current price of 58.7.
For the next year, analysts expect an EPS growth of 485.3% and a revenue growth 11.99% for PHO.OL